Photoredox catalysis, peptide therapeutics, biologics, targets, drug discovery, Pharma, Pharma, Bloom, Steve Bloom, The Bloom Group, KU, Science, Peptides, research, unnatural amino acids, peptide libraries, biocompatible photocatalysts, tethering biomolecules, chemotherapeutics, photochemical strategies, fusion proteins, antibody conjugates, bi-specific peptides, light activated molecules, electron oxidation, synthetic radical intermediates, therapeutic scaffolds, medicinally relevant compounds, bio-derived therapeutics, small cell lung cancer, viral capsid, improved therapeutics,

KU SCIENCE

THE BLOOM GROUP

Streamlining Biopharmaceutical Drug Discovery through the use of Bioinspired Photoredox catalysts.

RECENT NEWS FROM THE GROUP:

Steven Bloom Promoted to Associate Professor 2025

Samuel Gary Defends Thesis & Begins a Postdoc @ UT Dallas 2025

Alonso Rodriguez Defends Thesis and Joins Bicycle 2025

Jacob Immel Defends Thesis and Begins a Faculty Position at SBU 2024

Steven Bloom named Thieme Chemistry Journal Awardee 2021

Alonso Rodriguez wins Gregory and Francis Lauver Medicinal Chemistry Fellowship 2020

Maheshwerreddy Chilamari and Jacob Immel publish in ACS Catal. 2020

Samuel Gary named Chemical Biology of Infectious Disease NIH Trainee 2020

Jacob Immel wins Lester and Betty Mitscher Prize for Excellence in Medicinal Chemistry 2020

Jacob Immel wins Gregory and Francis Lauver Medicinal Chemistry Fellowship 2019

Jacob Immel named Madison and Lila Self Graduate Fellow 2019-2023